The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Studies with glycolysis-deficient cells suggest that production of lactic acid is not the only cause of tumor acidity.
Open accessAbstract
Solid tumors have been observed to develop an acidic extracellular environment, which is believed to occur as a result of lactic acid accumulation produced during aerobic and anaerobic glycolysis. Experiments using glycolysis-deficient ras-transfected Chinese hamster lung fibroblasts have been performed to test the hypothesis that lactic acid production within solid tumors is responsible for the development of tumor acidity. The variant cells have defects in glucose transport and in the glycolytic enzyme phosphoglucose isomerase with 1% activity compared to parental cells. Consequently, the in vitro rate of lactic acid production by variant cells was < 4% compared to parental cells. An in vitro correlation between lactic acid production and acidification of exposure medium was observed for parental and variant cells. Implantation of both cell lines into nude mice led to tumors with minimal difference in growth rate. As expected, variant cells died when exposed to hypoxic conditions in culture, and parental tumors were observed to have a larger fraction of cells resistant to radiation due to hypoxia (27%) than variant tumors (2%). Using pH microelectrodes, parental (n = 12) and variant (n = 12) tumors were observed to have extracellular pH (pHe) values of 6.65 +/- 0.07 and 6.78 +/- 0.04 (mean +/- SE, P = 0.13), respectively, whereas normal muscle had a pHe of 7.29 +/- 0.06 (P < 0.0001 for both cell lines). The lactic acid content of variant tumors was found to be similar to that in serum, whereas parental tumors had lactic acid content that was higher than in serum (P < 0.0001). We conclude that there was no correlation between lactic acid content and acidosis for these tumors derived from ras-transfected fibroblasts. These results provide evidence that the production of lactic acid via glycolysis is not the only mechanism responsible for the development of an acidic environment within solid tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tannock, I. F. (1968) · British Journal of Cancer · doi:10.1038/bjc.1968.34 · Cited by 763
Self-citation
Cited by
Hypoxia signalling in cancer and approaches to enforce tumour regression
Pouysségur, J., Dayan, F., & Mazure, N. M. (2006) · Nature · doi:10.1038/nature04871 · Cited by 1,676
Self-citationNanomaterials for Theranostics: Recent Advances and Future Challenges
Lim, E.-K., Kim, T., Paik, S., Haam, S., Huh, Y.-M., & Lee, K. (2015) · Chemical Reviews · doi:10.1021/cr300213b · Cited by 1,233
Tumour acidosis: from the passenger to the driver's seat
Corbet, C., & Feron, O. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.77 · Cited by 988
Causes and consequences of tumour acidity and implications for treatment
Stubbs, M., McSheehy, P. M. J., Griffiths, J. R., & Bashford, C. L. (2000) · Molecular Medicine Today · doi:10.1016/s1357-4310(99)01615-9 · Cited by 778
Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH
Švastová, E., Hulı́ková, A., Rafajová, M., Zat'ovičová, M., Gibadulinová, A., Casini, A., Cecchi, A., Scozzafava, A., Supuran, C. T., Pastorek, J., et al. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.10.043 · Cited by 711
Zeolitic imidazolate framework-8 as efficient pH-sensitive drug delivery vehicle
Sun, C.-Y., Qin, C., Wang, X.-L., Yang, G.-S., Shao, K.-Z., Lan, Y.-Q., Su, Z.-M., Huang, P., Wang, C.-G., & Wang, E.-B. (2012) · Dalton Transactions · doi:10.1039/c2dt30357d · Cited by 710
Tumour hypoxia induces a metabolic shift causing acidosis: a common feature in cancer
Chiche, J., Brahimi‐Horn, M. C., & Pouysségur, J. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00994.x · Cited by 667
Self-citationMechanisms of resistance to cisplatin and carboplatin
Stewart, D. J. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.02.001 · Cited by 631
Causes and Consequences of Increased Glucose Metabolism of Cancers
Gillies, R. J., Robey, I., & Gatenby, R. A. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.047258 · Cited by 623
Regulation of tumor pH and the role of carbonic anhydrase 9
Swietach, P., Vaughan-Jones, R. D., & Harris, A. L. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9064-0 · Cited by 539
“negligible in vitro lactic acid production [55].”
The chemistry, physiology and pathology of pH in cancer
Swietach, P., Vaughan-Jones, R. D., Harris, A. L., & Hulikova, A. (2014) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2013.0099 · Cited by 539
Recent advances in apoptosis, mitochondria and drug resistance in cancer cells
Indran, I. R., Tufo, G., Pervaiz, S., & Brenner, C. (2011) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2011.03.010 · Cited by 526
Analysis and Interpretation of Microplate-Based Oxygen Consumption and pH Data
Divakaruni, A. S., Paradyse, A., Ferrick, D. A., Murphy, A. N., & Jastroch, M. (2014) · Methods in Enzymology · doi:10.1016/b978-0-12-801415-8.00016-3 · Cited by 518
Chloroquine and its analogs: A new promise of an old drug for effective and safe cancer therapies
Solomon, V. R., & Lee, H. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.06.063 · Cited by 516
Dhup, S., Kumar Dadhich, R., Ettore Porporato, P., & Sonveaux, P. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212799504902 · Cited by 420
Riedl, S., Zweytick, D., & Lohner, K. (2011) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2011.09.004 · Cited by 405
pH control mechanisms of tumor survival and growth
Parks, S. K., Chiche, J., & Pouyssegur, J. (2011) · Journal of Cellular Physiology · doi:10.1002/jcp.22400 · Cited by 357
Corbet, C., Bastien, E., Santiago de Jesus, J. P., Dierge, E., Martherus, R., Vander Linden, C., Doix, B., Degavre, C., Guilbaud, C., Petit, L., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14262-3 · Cited by 330
The hypoxic tumour microenvironment and metastatic progression
Subarsky, P., & Hill, R. P. (2003) · Clinical & Experimental Metastasis · doi:10.1023/a:1022939318102 · Cited by 327
Hypoxia, cancer metabolism and the therapeutic benefit of targeting lactate/H(+) symporters
Marchiq, I., & Pouysségur, J. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-015-1307-x · Cited by 300
“[53] showed that glycolysis-deficient cells have similar extracellular pH (pHe) values than the ones of parental cells, in both in vitro and in vivo, even if the former produced less lactate.”
BackgroundSelf-citationAcid-Sensitive Ion Channels and Receptors
Holzer, P. (2009) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-540-79090-7_9 · Cited by 282
Cancer metabolism: The Warburg effect today
Ferreira, L. M. R. (2010) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2010.08.006 · Cited by 281
Tumor Acidity, Chemoresistance and Proton Pump Inhibitors
De Milito, A., & Fais, S. (2005) · Future Oncology · doi:10.2217/14796694.1.6.779 · Cited by 265
Hashim, A. I., Zhang, X., Wojtkowiak, J. W., Martinez, G. V., & Gillies, R. J. (2011) · NMR in Biomedicine · doi:10.1002/nbm.1644 · Cited by 265
Targeting Vacuolar H+-ATPases as a New Strategy against Cancer
Fais, S., De Milito, A., You, H., & Qin, W. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1805 · Cited by 264
PET-MR and SPECT-MR multimodality probes: Development and challenges
Yang, C.-T., Ghosh, K. K., Padmanabhan, P., Langer, O., Liu, J., Eng, D. N. C., Halldin, C., & Gulyás, B. (2018) · Theranostics · doi:10.7150/thno.26610 · Cited by 101
Metadata
- Authors
- Newell, K., Franchi, A., Pouysségur, J., & Tannock, I.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1993-02
- Volume
- 90
- Issue
- 3
- Pages
- 1127-1131
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2093828087
- Cited by
- 197
- References
- 1
- FWCI
- 0.95
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.